Wednesday, June 10, 2026

pharma Β· Advanced or metastatic solid tumors Β· WaldenstrΓΆm's Macroglobulinemia

BeiGene

BeiGene clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
Status
Public
HQ
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
Founded
2010
Employees
2,047
Programs
14
Drugs
19
Patents
25
Intelligence Β· Clinical Programs

BeiGene projects

3 ClinicalTrials.gov programs sponsored by BeiGene.

BeiGene has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BGB DXP593

    BeiGene

    Covid19

    phase 1 small molecule completed

    1 trial
  2. BGB-21447-101

    BeiGene

    mature B-Cell malignancies

    phase 1 other active

    1 trial
  3. BGB-A317-A3055-101

    BeiGene

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does BeiGene have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.